Drug Profile
Pamiparib - BeiGene
Alternative Names: BeiGene-290; BGB-290; BGB-290-BeiGene; PARPi - BeiGene; PARTRUVIXLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator BeiGene
- Developer BeiGene; Myriad Genetics
- Class Antineoplastics; Aza compounds; Fluorinated hydrocarbons; Ketones; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase III Cancer
- Phase II Gastric cancer; HER2 negative breast cancer
- Phase I/II Glioblastoma; Glioma; Solid tumours
- Suspended Prostate cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-0 development in Glioblastoma(Neoadjuvant therapy) in USA (PO, Capsule)
- 08 Feb 2024 BeiGene in collaboration with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and National Cancer Institute completes a phase I/II clinical trials in Glioma (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT03914742)
- 04 Oct 2023 BeiGene in collaboration with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and National Cancer Institute suspends phase I/II clinical trials in Glioma (Second-line therapy or greater, Combination therapy) in USA (PO), as NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer (NCT03914742)